Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer.

about

Differential expression of DUSP2 in left- and right-sided colon cancer is associated with poor prognosis in colorectal cancer.

Item

http://www.wikidata.org/entity/Q52655173

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Differential expression of DUS ...... rognosis in colorectal cancer.

@en

Differential expression of DUS ...... rognosis in colorectal cancer.

@nl

type

Item

label

Differential expression of DUS ...... rognosis in colorectal cancer.

@en

Differential expression of DUS ...... rognosis in colorectal cancer.

@nl

prefLabel

Differential expression of DUS ...... rognosis in colorectal cancer.

@en

Differential expression of DUS ...... rognosis in colorectal cancer.

@nl

P1476

Differential expression of DUS ...... rognosis in colorectal cancer.

@en

P2093

Na Li

http://www.w3.org/2001/XMLSchema#string

Wenjie Dong

http://www.w3.org/2001/XMLSchema#string

Xinai Wu

http://www.w3.org/2001/XMLSchema#string

Xiufeng Pei

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.

PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression.

Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells

Salubrinal acts as a Dusp2 inhibitor and suppresses inflammation in anti-collagen antibody-induced arthritis

Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2

The dual specificity phosphatase 2 gene is hypermethylated in human cancer and regulated by epigenetic mechanisms

Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab.

Biphasic activation of extracellular signal-regulated kinase (ERK) 1/2 in epidermal growth factor (EGF)-stimulated SW480 colorectal cancer cells.

RANKL/RANK pathway abrogates cetuximab sensitivity in gastric cancer cells via activation of EGFR and c-Src.

P304

4207-4214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.7881

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29541187

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5835964

http://www.w3.org/2001/XMLSchema#string